Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.28 NOK | +1.29% |
|
+4.67% | -18.44% |
May. 08 | ContextVision AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 08 | Transcript : ContextVision AB, Q1 2024 Earnings Call, May 08, 2024 |
Summary
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-18.44% | 44.78M | C- | ||
-3.40% | 29.42B | C | ||
+40.08% | 9.42B | C- | ||
+33.70% | 4.35B | B- | ||
-40.60% | 2.19B | C- | ||
-6.10% | 1.68B | - | C+ | |
-28.86% | 1.18B | B | ||
-43.96% | 968M | - | ||
-7.75% | 769M | C | ||
-48.70% | 679M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CONTX Stock
- Ratings ContextVision AB